Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC Open-Label Extension in Pemphigus
NCT04598477Phase 3Terminated
- Sponsor
- argenx
- Start
- Jul 2021
- Primary completion
- Mar 2024
- Modality
- Antibody Fragments
- Countries
- 21
01
Overview
A Phase 3 trial of efgartigimod alfa in pemphigus vulgaris (PV), pemphigus foliaceus (PF), sponsored by argenx. Started Jul 2021; status: terminated.
02
Drugs
efgartigimod alfa
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on NCT04598477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04598477.